Tolerability and safety of perampanel: Two randomized dose-escalation studies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F12%3AA120147V" target="_blank" >RIV/61988987:17110/12:A120147V - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Tolerability and safety of perampanel: Two randomized dose-escalation studies

Original language description

To evaluate, for the first time in patients with epilepsy, the tolerability and safety of escalating doses of oral perampanel, a novel, selective, non-competitive AMPA antagonist, as adjunctive therapy for refractory partial-onset seizures. Perampanel was well tolerated across doses of 4-12mg/day. The studies showed preliminary evidence of efficacy and identified doses to be evaluated in larger clinical studies

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

ACTA NEUROL SCAND

ISSN

0001-6314

e-ISSN

—

Volume of the periodical

125

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

8-15

UT code for WoS article

—

EID of the result in the Scopus database

—